Regulatory Evolution to Expedite Drug Development in Japan: A PMDA Initiatives

Why It Matters

Accelerated, transparent approvals and dedicated orphan pathways make Japan a more attractive market for global pharma, helping to curb drug loss and drive innovation in rare‑disease treatments.

Key Takeaways

• PMDA review times have shortened dramatically since 2004
• 35% of US‑approved drugs lack Japanese market approval
• New “open drug” criteria and pediatric orphan center launched 2024
• Orphan drug designations doubled in 2024, expected to rise further
• PMDA now offers English consultations and accepts English submissions worldwide

Summary

The video outlines PMDA’s latest regulatory reforms aimed at accelerating drug development in Japan. Since its 2004 inception, the agency has cut review cycles dramatically, yet a growing “drug loss” problem persists as 35% of drugs approved in the United States never reach the Japanese market. To counter this, PMDA, in partnership with the Ministry of Health, Labor and Welfare, introduced open‑drug designation criteria and launched the Consultation Center for Pediatric and Orphan Drug Development (CCPOD) in 2024, doubling orphan designations year‑over‑year. Key data points include a 290‑day average from application to approval in 2024—among the shortest globally—and a 60‑to‑90‑day pricing decision window under the national health insurance system. International collaboration has expanded with bilateral ties to the FDA and EMA, the opening of a Bangkok office in July 2024 and a Washington, D.C. office in November 2024, and the provision of free English‑language regulatory consultations for companies lacking a Japanese presence. Notable examples cited are the Minister’s January 2024 clarification of open‑drug criteria, the July 2024 establishment of CCPOD, and the QR‑coded links directing viewers to an English PMDA website and the source paper. These moves illustrate PMDA’s commitment to harmonized standards, transparent timelines, and accessible information for global innovators. The implications are clear: faster, more predictable approvals and pricing bolster Japan’s appeal as a launch market, while targeted orphan and pediatric pathways aim to reduce drug loss and stimulate investment in rare‑disease therapies. Enhanced English support and international offices lower entry barriers, positioning Japan as a competitive hub for innovative pharmaceuticals.

Original Description

【Research Introduction Video】

This video highlights PMDA’s initiatives to promote understanding of Japan’s regulatory system among overseas startups, support drug development including in Japan, and help address challenges such as "Drug Loss".

This video supplements the contents of a paper reported by PMDA experts in 2025, and introduces the current PMDA’s initiatives to expedite drug development in Japan. We hope you enjoy watching.

【Link】

https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.70022

（Clinical Pharmacology & Therrapeutics）